Literature DB >> 6889574

Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.

N F Pierce, W C Cray, J B Sacci.   

Abstract

The immunogenicity and safety of purified cholera toxin (CT), its B subunit, and a crude culture filtrate of toxigenic Vibrio cholerae (CrT) were compared in dogs immunized orally and challenged with virulent V. cholerae. CT and CrT caused marked protection in two- or three-dose regimens. Protection due to CT occurred only with doses that caused transient, sometimes severe, diarrhea in most dogs; this protection was proportional to the peak antitoxin response in jejunal mucosa and lasted at least 15 weeks. In contrast, minimum protective doses of CrT contained much less cholera toxin, caused very mild diarrhea in only 21% of the dogs, and evoked protection that was greater than predicted from the modest jejunal antitoxin response. B subunit caused smaller jejunal antitoxin responses than did similar doses of CT and was poorly protective, the 50% protective dose being >40-fold greater than that of CT. Two observations indicated that protection due to CrT involved synergy between antibacterial and antitoxic immune responses. First, the 50% protective dose of CrT was 24-fold and >36-fold smaller than the 50% protective doses of its CT and non-CT antigenic components, respectively, when tested separately. Second, protection was greater in CrT-immunized dogs than in CT-immunized dogs for a given mucosal antitoxin response. Low doses of CrT evoked serotype-specific protection, indicating that the serotype-specific O somatic antigen contributed significatly to antibacterial protection. These results suggest that a simple, effective, nonliving oral vaccine for cholera based on combined antibacterial and antitoxic immunity can probably be achieved. However, further studies are needed to determine how a protective antitoxic response can be evoked without causing diarrhea during immunization.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889574      PMCID: PMC347586          DOI: 10.1128/iai.37.2.687-694.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Protection against experimental cholera by oral or parenteral immunization.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats.

Authors:  N F Pierce; F T Koster
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

Review 3.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

4.  Intestinal immune response to cholera toxin: dependence on route and dosage of antigen for priming and boosting.

Authors:  A M Svennerholm; S Lange; J Holmgren
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

5.  Duration of infection-derived immunity to cholera.

Authors:  M M Levine; R E Black; M L Clements; L Cisneros; D R Nalin; C R Young
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

6.  Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

7.  Antitoxic immunity to cholera in dogs immunized orally with cholera toxin.

Authors:  N F Pierce; W C Cray; P F Engel
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

8.  Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera.

Authors:  N F Pierce; W C Cray; B K Sircar
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

9.  Special features of the priming process for a secretory IgA response. B cell priming with cholera toxin.

Authors:  J A Fuhrman; J J Cebra
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

10.  The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats.

Authors:  N F Pierce
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  30 in total

1.  Determinants of immunogenicity and mechanisms of protection by virulent and mutant Vibrio cholerae O1 in rabbits.

Authors:  N F Pierce; W C Cray; J B Kaper; J J Mekalanos
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

2.  Comparison of the reactivities and immunogenicities of procholeragenoid and the B subunit of cholera toxin in Thai volunteers.

Authors:  S Migasena; P Pitisuttitham; P Suntharasamai; B Prayurahong; W Supanaranond; V Desakorn; R E Black
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

3.  Effect of nicotine on secretory component synthesis by secretory epithelial cells.

Authors:  R L Gregory; L E Gfell
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

4.  Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization.

Authors:  I de Zoysa; R G Feachem
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  Enhanced mucosal priming by cholera toxin and procholeragenoid with a lipoidal amine adjuvant (avridine) delivered in liposomes.

Authors:  N F Pierce; J B Sacci
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

6.  Successful colonization and immunization of adult rabbits by oral inoculation with Vibrio cholerae O1.

Authors:  W C Cray; E Tokunaga; N F Pierce
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

7.  Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.

Authors:  R E Black; M M Levine; M L Clements; C R Young; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

8.  Protective secretory immunoglobulin A antibodies in humans following oral immunization with Streptococcus mutans.

Authors:  R L Gregory; S J Filler
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

9.  Compared colonizing and immunizing efficiency of toxinogenic (A+ B+) Vibrio cholerae and an A- B+ mutant (Texas Star-SR) studied in adult rabbits.

Authors:  E Tokunaga; W C Cray; N F Pierce
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.

Authors:  F M Apter; P Michetti; L S Winner; J A Mack; J J Mekalanos; M R Neutra
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.